Humira (adalimumab) can be prescribed in children who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid and an immunomodulator, or who are intolerant to or have contraindications for such therapies.
Children weighing less than 40kg should receive an initial dose of 40mg followed by a 20mg dose two weeks later. Dosing should then be continued at 20mg on alternate weeks, increasing to 20mg once weekly if necessary. In children weighing 40kg or more the recommended dose is 80mg initially followed by 40mg two weeks later, then 40mg every one or two weeks. Humira is given by subcutaneous injection.
Further information: AbbVie Ltd